Brief: Artivion Follows Recommendation To Stop Proact Xa Clinical Trial

Artivion

23/09/2022 12:12

Sept 23 (Reuters) - Artivion Inc  AORT.N :
    * ARTIVION FOLLOWS RECOMMENDATION TO STOP PROACT XA CLINICAL
TRIAL
    * ARTIVION INC - STUDY WAS EVALUATING USE OF APIXABAN IN
PATIENTS
TREATED WITH MECHANICAL AORTIC VALVES
    * ARTIVION INC - DECISION WAS BASED ON RECOMMENDATION OF
INDEPENDENT DATA AND SAFETY MONITORING BOARD OF TRIAL DUE TO
LACK OF EVIDENCE
    * ARTIVION -  DSMB OF TRIAL SUGGESTED LACK OF EVIDENCE
SUPPORTING
NON-INFERIORITY OF APIXABAN TO WARFARIN FOR VALVE THROMBOSIS AND
THROMBOEMBOLISM
    * ARTIVION INC - DESPITE STOPPING TRIAL, WE ARE REITERATING
OUR
2022 OUTLOOK OF DELIVERING DOUBLE-DIGIT TOP-LINE GROWTH

Source text for Eikon:  ID:nPnccxV6da 
Further company coverage:  AORT.N 
 ((Reuters.Briefs@thomsonreuters.com;))